Alnylam Pharmaceuticals, Inc. (ALNY)
Makes medicines that silence disease-causing genes using RNA interference technology.
$288.41+0.04%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-28.2%
The outlook
Analysts overwhelmingly favor ALNY with a Buy consensus and an average price target about 50% above current levels. The stock is trading well below both its 50- and 200-day moving averages and sits near the lower end of its 52-week range, suggesting a downtrend in the near term. The valuation reflects a high trailing P/E of 72.5, typical for biotech companies with growth expectations.
What’s behind the score
Analyst consensusBuy — 1.8 avg of 23 analysts
Price trendBelow its 50- & 200-day averages
52-week range11% of the way from its 52-week low to high
Price targetAvg target +50% vs current price
Analyst price target
~12-month · 23 analysts$432.04average target+49.8% vs now
Now $288.41
Low $285.00High $551.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$38.51B
52-wk high
$495.55
52-wk low
$262.21
50-day avg
$291.63
200-day avg
$353.53
Trailing P/E
72.5